-
Buljevac and colleagues assessed whether life events that are perceived as stressful by patients themselves are associated with exacerbations.
-
This study corroborates a few earlier studies indicating that sympathetic vasomotor dysfunction may have a role in MS-related fatigue.
-
Insulin Plus Metformin vs Triple Oral Therapy in Type 2 Diabetes; ARB
and ACE-I in Diabetic Nephropathy; Low-Glycemic Index Diets and
Diabetes; Ultralow-Dose Estrogen and Bone in Older Women; Effect of
Intensity of Oral Anticoagulation in Atrial Fibrillation; Patient
Knowledge and Awareness of Hypertension
-
A generic form of paroxetine (PaxilGlaxoSmithKline) will soon be on the market.
-
-
Drs. Gregg Stone and Stephen Ellis presented the 9-month clinical and angiographic results from TAXUS IV, which was designed to assess the safety and efficacy of the TAXUS slow-release polymer-based paclitaxel-eluting Express2 stent (Boston Scientific) in a broad cross-section of patients.
-
Sertraline contributed to a decrease in platelet activation over and above either aspirin or thienopyridines, and the SSRI might represent an attractive additional advantage for patients with depression and comorbid coronary artery disease and stroke.
-
-
The 3 CHARM studies (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) and their combined results were presented at the ESC meeting and published in Lancet in September.
-
The European Trial of Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease (EUROPA) study tested the hypothesis that perindopril in patients with stable coronary artery disease, but without heart failure or substantial hypertension, will reduce cardiovascular deaths, myocardial infarction, and cardiac arrest.
